Metastatic Melanoma: The New Millennium

Metastatic Melanoma: The New Millennium

Episodes

Specialty:

All

Year:

All

EP. 1: Systemic Therapy with T-VEC in Advanced Melanoma

December 16th 2015

EP. 2: Practical Application of T-VEC in Melanoma Treatment

December 16th 2015

EP. 3: Radiation Therapy and Abscopal Effect in Melanoma Treatment

December 16th 2015

EP. 4: Role of Surgery in the Management of Advanced Melanoma

December 16th 2015

EP. 5: Use of Immunotherapy Agents in Melanoma Treatment

December 16th 2015

EP. 6: Sequencing of Checkpoint Agents in Melanoma

December 16th 2015

EP. 7: Duration of Immunotherapy in Melanoma

December 16th 2015

EP. 8: Checkpoint Inhibitors: Combination Therapy in Melanoma

December 16th 2015

EP. 9: Combination Immunotherapy Treatment Duration in Melanoma Patients

December 16th 2015

EP. 10: Treatment of BRAF-Mutant Metastatic Melanoma

December 16th 2015

EP. 11: Sequencing Dual BRAF-MEK Inhibition and Immunotherapy

December 16th 2015

EP. 12: Duration of Dual BRAF-MEK Inhibition in Melanoma

December 16th 2015

EP. 13: Hot Versus Cold Tumors: Predictive Markers in Melanoma

December 16th 2015

EP. 14: Future Advances in Melanoma Treatment

December 16th 2015

Trending on OncLive

Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ESMO 2026

FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL

Tocilizumab Prophylaxis, Caregiver Readiness, and Chair Time Shape Community Bispecific Programs in R/R Myeloma

Generic Venetoclax Gains Final FDA Approval in CLL/SLL and Newly Diagnosed AML

Phase 1 Study of BGB-B2033 (GPC3 x 4-1BB Bispecific Antibody) Monotherapy: First Disclosure of Dose Optimization and Dose Escalation Update in Advanced Hepatocellular Carcinoma